1 hour ago
1
alexsl
Centessa Pharmaceuticals (NASDAQ:CNTA) has been rated as Outperform at Oppenheimer, reflecting strong conviction in the company's lead asset, ORX750, an orexin-2 receptor agonist.
This upgrade comes ahead of the anticipated phase 2a CRYSTAL-1 trial data expected by Q4 2025, which will
English (US) ·